BMT CTN 0901
fludarabine plus busulfan; fludarabine plus melphalan in acute myeloid leukemia or myelodysplastic syndrome
BMT CTN 0901 compares myeloablative with reduced-intensity conditioning before donor transplantation, asking which improves survival in adults with AML or MDS. Commentary comes from X posts, a podcast and YouTube interviews, including medical oncologists with confirmed clinical roles. The discussion turns on when fitness supports myeloablative conditioning in older patients, unresolved questions about MRD assays for intensity selection, and disagreement over delaying transplantation to clear residual disease.
- NCT01339910 ↗
- v1.0.0 · edition 1
- updated Oct 31, 2026
- Focused
6 findings, and what sits behind each
01. Better outcomes with MRD negativity do not establish that delaying transplantation to clear MRD helps
10 statements · 10 passages · 1 sources · 8 named voices
Counterview: recorded · Limitations recorded: 3. Feeds the Medical Affairs question.
Draws on: The comparison.
02. The preference for MAC is conditional on fitness, with explicit concern about overextension to older patients
24 statements · 18 passages · 12 sources · 14 named voices
Counterview: recorded · Limitations recorded: 3. Feeds the Medical Affairs question.
Draws on: Population and setting, The comparison, Safety and tolerability, Secondary endpoints, Primary endpoint: Percentage of Participants With Overall Survival (OS).
03. MRD-dependent intensity choices attract interest, but the statements do not support blanket equivalence
13 statements · 10 passages · 6 sources · 7 named voices
Counterview: recorded · Limitations recorded: 3. Feeds the Medical Affairs question.
Draws on: The comparison, Primary endpoint: Percentage of Participants With Overall Survival (OS), Population and setting, Design and conduct.
04. MRD assessment is valued, while assay comparability and the evidence needed to act remain unsettled
13 statements · 7 passages · 4 sources · 4 named voices
Counterview: none recorded · Limitations recorded: 3. Feeds the Medical Affairs question.
Draws on: Design and conduct, Population and setting.
05. Endpoint choice, statistical power and regimen classification complicate reconciliation across studies
16 statements · 10 passages · 8 sources · 8 named voices
Counterview: recorded · Limitations recorded: 3. Feeds the Medical Affairs question.
Draws on: Design and conduct, The comparison, Primary endpoint: Percentage of Participants With Overall Survival (OS), Population and setting, Secondary endpoints.
06. Regimen-level toxicity, organ function and post-transplant support qualify the intensity decision
15 statements · 6 passages · 4 sources · 3 named voices
Counterview: recorded · Limitations recorded: 4. Feeds the Medical Affairs question.
Draws on: Safety and tolerability, The comparison, Population and setting, Secondary endpoints, Primary endpoint: Percentage of Participants With Overall Survival (OS).
Counts overlap, since one statement can back several findings. They show what the report kept, not how many clinicians agree. The full report includes the interpretations and source links.
Select a finding to see what the full report holds for it: how many verified HCP statements and of what kind, the passages behind them, the sources and voices, and the counterview and limits it records. Select a part of the trial to see which findings draw on it.
- Finding 1 of 6
Better outcomes with MRD negativity do not establish that delaying transplantation to clear MRD helps
- statements
- 10
- passages
- 10
- sources
- 1
- named voices
- 8
What the statements areViews 6Questions and uncertainty 2Clinical experience 1Comparisons 1Restated results and context 0How passages are usedSupporting a statement 10Giving context 0Recorded with the finding- Counterview: recorded
- Limitations: 3
- Feeds the Medical Affairs question
- 1 post or article
Draws on: The comparison.
In the full report: the interpretation in full, all 10 statements cited to source and date, and the 1 source linked where public.
Thicker lines mean more shared statements. A finding without a line goes beyond the registered design. Counts overlap, since one statement can back several findings, and they show what the report kept, not how many clinicians agree.
The full BMT CTN 0901 report gives each finding its interpretation, the attributed views behind it, counterviews, limits and the verified HCP statements, each linked to the original. Get a complete report free to see what you get.
How should Medical Affairs distinguish evidence for an MRD-informed conditioning choice from evidence for delaying transplantation to clear MRD, while keeping fitness, readiness and access explicit?
Raised by the leading finding. The report shows what clinicians said and the sources behind it; it does not settle the question.
By the numbers
free- 42HCP commentary sources screened
- 27sources cited by verified HCP statements
- 30named in screened sources
- 30voices cited in the report
- 24cited voices matched to verified clinician profiles
Also in the sources: 1 organizational or shared account, not counted as people.
- 91verified statements, each linked to its source
- 40of them from speakers with a confirmed clinical role
- 6findings
Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context. No count estimates how many clinicians hold a view. Size (Focused) is set by the 91 verified statements. Statements from sponsors, hosts and organisations are labelled and count apart from identified clinicians. A confirmed clinical role is one verified by the NPI registry or by the person's own institution's staff page; a role a source only states is not counted.
What's inside
free| Section | Items | Access |
|---|---|---|
| Findings with interpretation, counterviews and limits | 6 | Titles free |
| Detailed analysis | 7 sections | Paid |
| Verified statements with short source quotes and links | 91 | Paid |
| Trial aspects mapped | 11 | Free |
| Sources with links | 27 | Counts free |
| Speaker attribution for cited voices | 30 | Paid |
Trial aspects
11 discussed · 0 no commentary · 0 incomplete| Aspect | Statements | Sources |
|---|---|---|
| Primary endpoint: Percentage of Participants With Overall Survival (OS) | 7 | 4 |
| Secondary endpoints | 9 | 5 |
| Population and setting | 20 | 10 |
| The comparison | 28 | 13 |
| Safety and tolerability | 15 | 6 |
| Design and conduct | 12 | 6 |
| MRD-dependent intensity selection and assay interpretation | 22 | 8 |
| Immediate allo versus additional MRD-directed treatment | 11 | 2 |
| RICMAC, German AML comparisons and broader intensity classification | 8 | 5 |
| Maintenance, surveillance and patient support around transplantation | 8 | 2 |
| Evidence awareness, historical availability and research priorities | 11 | 7 |
An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.
Sources
free| Channel | Screened | Cited | |
|---|---|---|---|
| X threads | 39 | 20 | |
| YouTube | 2 | 2 | |
| Podcasts | 1 | 1 | |
| Primary sources, cited for context, not screened | |||
| Registry | not screened | 3 | |
| Publications | not screened | 1 | |
max 8 / quarter
- Screened window
- Feb 12, 2015 → Aug 20, 2026
- Cited window
- Sep 19, 2015 → Aug 20, 2026
- Retrieved
- Oct 31, 2026
The trial
from ClinicalTrials.gov- Title
- A Randomized, Multi-Center, Phase III Study of Allogeneic Stem Cell Transplantation Comparing Regimen Intensity in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia (BMT CTN #0901)
- Registry
- NCT01339910
- Study IDs
- BMTCTN0901 · U01HL069294 · U01HL069294-05 · BMT CTN 0901 (Blood and Marrow Transplant Clinical Trial Network) · 5U24CA076518
- Sponsor
- Medical College of Wisconsin
- Collaborators
- National Heart, Lung, and Blood Institute (NHLBI), National Cancer Institute (NCI), Blood and Marrow Transplant Clinical Trials Network, National Marrow Donor Program
- Design
- Phase 3 · Interventional, randomized, parallel
- Status
- Terminated
- Enrollment
- 272 actual
- Registered
- 2011-04-21
- Start
- 2011-06 actual
- Primary completion
- 2017-01-16 actual
- Primary endpoint
- Percentage of Participants With Overall Survival (OS)
- Interventions
- 5 registered
Scope and limits
freeThis report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.
- Discussion that does not name the trial may be missing from this edition.
- Not yet captured in this edition: a question about transplant consolidation selection based on fitness, prior therapy, donor availability and residual disease testing.
- Not yet captured in this edition: a question about transplant conditioning selection in AML with prior refractory disease, persistent fungal lung cavities and a matched sibling donor.
- Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
- 29 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.
- This edition describes the sources reviewed, not the prevalence of views among HCPs or a professional consensus. Reposts and relayed presentations are not independent endorsements.
- Some potentially relevant passages were not fully assessed. Discussions without the trial's name or identifier, or using different transcriptions, may be missing.
- Full text was unavailable for two referenced publications. The primary results abstract was available, but detailed long-term and MRD interpretations here rely substantially on attributed commentary.
- Several brief replies lack the proposition or answer option needed to determine a specific clinical recommendation.
- Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
- The a YouTube channel interview's spoken passages cannot be assigned to a named person from the available evidence.
- The statements come from different dates and clinical exchanges. Their order does not establish a change of mind, and historical statements about unavailable evidence are not current statements of absence.
- Only some interventions were checked for regulatory information, and exact combination labels were not located. No conclusion about regulatory status or absence of an applicable label can be drawn.
How reports are built and checked: Methods.
Editions and corrections
freeLast checked for new commentary Oct 31, 2026. A new or changed finding gets a new version number; added evidence alone is a smaller update. No corrections.
Cite this report
Erudio Health. BMT CTN 0901 (NCT01339910): HCP commentary report. Edition 1, v1.0.0. Accepted Oct 31, 2026. https://www.erudio.com/reports/bmt-ctn-0901-nct01339910
For your AI agent
Paste this into ChatGPT, Claude, Microsoft Copilot or your own agent. It previews this report through the free Erudio MCP server, tells you whether it answers your question, and orders it if you ask. Some agents ask you to confirm pasted instructions before acting; that is expected.
Help me decide whether to buy the Erudio report "BMT CTN 0901" (NCT01339910), and buy it for me if I ask. Erudio reports cover what clinicians say in public about one clinical trial, with every verified statement linked to its source.
1. Use the free Erudio MCP server at https://mcp.erudio.com/free; it needs no sign-in. Nothing needs installing: if it is not connected in this app and you can make HTTP requests, call it directly with JSON-RPC POSTs to that URL (initialize, then tools/call), sending "Accept: application/json, text/event-stream". Call get_report_card with slug "bmt-ctn-0901-01339910". If you cannot make requests, read https://www.erudio.com/reports/bmt-ctn-0901-nct01339910.md instead.
2. In a few lines, tell me what the report covers: its findings, its verified statements and sources, its evidence window, what it leaves out, and the price of each product (offer). Then ask what I need it for, and say plainly whether this report answers it.
3. If I want it, ask for my work email and the product: the current edition, or 3, 6 or 12 months of weekly updates. Call create_order with report "NCT01339910", that product and email, then show me the quote and the checkout_url to pay by card. If you have a payment client for HTTP 402 payments and I agree, you can pay the pay_url instead. Nothing is charged until one is paid.
4. Once it is paid, call get_order with the status_url: it returns my license key. Then use the Erudio MCP server at https://mcp.erudio.com/mcp with the header "Authorization: Bearer <key>". Call read_report with report_id erudio-nct01339910 and sections ["all"], and summarize the findings for me with their sources. The full report is large (about 500 KB): save the response to a file and work from it rather than printing it. If you cannot, read sections ["narratives"] first, the executive summary and analysis.
When you tell me what clinicians said, give each view as theirs, with its source. Counts are the sources the report kept, not the share of clinicians who agree. Reports are not medical advice.
Keep the key private to my organization.Or read the record directly: JSON, Markdown or MCP
curl https://www.erudio.com/reports/bmt-ctn-0901-nct01339910.json
curl https://www.erudio.com/reports/bmt-ctn-0901-nct01339910.md
# MCP, no sign-in (https://mcp.erudio.com/free)
get_report_card({ "slug": "bmt-ctn-0901-01339910" })release f5ae87d63678b5a7e28963ca8c6b546e9d55fffe990f89489fe71f1033d8c6f9